Back to search

Celebrex

By Reinhard Angelmar,  Maiken Engsbye
Published 11 Jan 2006
Reference 5403
Topic Marketing
Industry Pharmaceuticals
Region North America
Length 22 page(s)
Language English
Inspection copy
6.00
Add to cart
Summary

The case describes the development and US launch of Celebrex, the first Cox-2 inhibitor, which is co-promoted by Pfizer and Searle. The launch was phenomenally successful. However, four months after launch Celebrex is facing three issues: (1) How to address the mix-ups between Celebrex and two drugs with similar names? (2) How to respond to media reports about deaths and serious side effects associated with Celebrex, which was positioned on safety? (3) How to prepare for the impending entry of Merck & Co's Vioxx?

Teaching objectives

Highlight the importance of preparing the market for a new product category Developing a marketing strategy for a pioneer that takes two types of competitors into account: (1) existing products from a different category; (2) follower products in the same category as the pioneer Dealing with product safety issues Pioneer - follower competitive dynamics

Keywords
  • RD1106
  • AR2006
  • AR0607
  • HMI
  • Pharmaceutical and Medical Device Sectors
About the authors
Angelmar

Reinhard Angelmar

Emeritus Professor of Marketing

Maiken  Engsbye


Recommended Cases

Gardasil Launch

By  Reinhard Angelmar,  Juliana Kim,  Michael Schroeder
Add to cart
Merck & Co is preparing the launch of Gardasil, the first human papillomavirus (HPV) vaccine. Because knowledge of HPV is poor among potential vaccinees and other stakeholders (parents, physicians, third-party payers), and there is no habit of vaccinating adolescents, Merck needs to develop pre-launch programmes.
    View case

    Amgen Europe in the Renal Anaemia Treatment Market

    By  Reinhard Angelmar,  Olivier Baron,  Elizabeth Chen,  Gaurav Batti
    Add to cart
    Amgen Europe has launched Aranesp, a second-generation EPO product in a market dominated by Johnson & Johnson's pioneering Eprex (US name Procrit), followed by NeoRecormon from Roche. One year after the launch, the sales and market share of Aranesp are below target.
      View case

      Baycol/Lipobay: A Prescription for Trial

      By  Reinhard Angelmar,  Efrat Zohar
      Add to cart
      Initially available only in low doses, sales of the aggressively priced Baycol/Lipobay anti-cholesterol drug pick up when the product is marketed at higher doses, especially in the large US market. On course for €1 billion sales, the product is withdrawn worldwide in response to reports of a number of deaths associated with its use.
        View case